Our Pricing

What Results Can You Expect from Mounjaro?

Understanding Mounjaro results UK weight loss outcomes helps set realistic expectations before starting treatment. Clinical trial data shows patients achieved average weight reductions of 15% to 22.5% over 72 weeks, with results varying based on dosage, lifestyle factors, and individual response [1]. At Cured Pharmacy, our UK prescribers provide transparent guidance on what you can genuinely expect from tirzepatide treatment, with prices starting from £135.00.

Clinical Trial Results: What the Evidence Shows

The landmark SURPASS-1 through SURPASS-5 trials provide the most comprehensive data on Mounjaro results UK patients can reference when considering treatment [1]. These phase 3 studies enrolled over 6,000 participants across multiple countries, including UK sites, and tracked outcomes over 40 to 72 weeks.

In SURPASS-3, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% from baseline over 72 weeks [1]. Those on the 10mg dose averaged 19.5% weight loss, whilst the 5mg dose produced 15% average reduction. Importantly, these results included patients who discontinued treatment, making them realistic indicators of real-world outcomes rather than best-case scenarios.

The SURMOUNT-1 trial, which specifically studied tirzepatide for weight management in adults without diabetes, demonstrated even more striking results [2]. Participants lost an average of 20.9% body weight on the 15mg dose over 72 weeks, compared to 3.1% in the placebo group. Approximately 50% of patients achieved at least 20% weight loss, whilst 89% achieved at least 5% reduction.

Mounjaro Weight Loss Timeline: When Results Appear

Most patients notice initial appetite suppression within the first week of starting Mounjaro, though measurable weight loss typically becomes evident from week 4 onwards [1]. The medication follows a gradual dose escalation schedule, starting at 2.5mg weekly and increasing every 4 weeks until reaching your maintenance dose.

During the first 12 weeks, patients in clinical trials lost an average of 5-7% of their starting weight, with results accelerating as doses increased [2]. The most significant weight reduction occurred between weeks 12 and 36, as participants reached higher maintenance doses of 10mg or 15mg weekly.

Peak weight loss typically occurs around 72 weeks (approximately 16-18 months) of continuous treatment, after which weight stabilises [1]. This extended timeline reflects how tirzepatide works—by gradually resetting appetite regulation and metabolic function rather than producing rapid, unsustainable drops.

What Affects Your Individual Timeline

Your personal Mounjaro results timeline depends on several factors your UK prescriber will discuss during consultation. Starting weight significantly influences outcomes—those with higher baseline BMI often see larger absolute weight reductions, though percentage losses remain consistent across weight categories [2].

Adherence to the dosing schedule, dietary modifications, and physical activity levels all impact results. Clinical trials showed patients who combined tirzepatide with structured lifestyle interventions achieved 2-3% greater weight loss than medication alone [1]. Previous weight loss attempts, metabolic health status, and concurrent medications also play roles in individual response rates.

Comparing Mounjaro Results to Other Weight Loss Treatments

Head-to-head trials demonstrate Mounjaro produces superior weight loss compared to semaglutide-based treatments like Wegovy. In SURPASS-2, participants on tirzepatide 15mg lost an average of 12.4kg more than those receiving semaglutide 1mg over 40 weeks [3].

This advantage stems from tirzepatide's dual mechanism—it activates both GIP and GLP-1 receptors, whilst semaglutide targets only GLP-1 pathways [3]. The additional GIP activation appears to enhance insulin secretion, improve fat metabolism, and produce greater satiety signals, translating to better clinical outcomes for most patients.

Compared to older weight loss medications like Orlistat, which blocks approximately 25% of dietary fat absorption, Mounjaro addresses weight loss through multiple metabolic pathways [4]. Orlistat typically produces 5-10% weight reduction, significantly less than the 15-22.5% average seen with tirzepatide in clinical trials.

Factors That Influence Your Mounjaro Results

Your final maintenance dose represents the most significant predictor of weight loss outcomes. Clinical data shows a clear dose-response relationship—higher doses produce greater average weight reduction, though individual tolerance and side effects determine the optimal dose for each patient [1].

Baseline metabolic health affects how quickly you respond to treatment. Patients with insulin resistance or pre-diabetes often experience more dramatic improvements in metabolic markers alongside weight loss, whilst those with healthier baseline metabolic function may see steadier, more gradual results [2].

Lifestyle factors remain crucial even with medication support. The SURMOUNT-1 trial included a reduced-calorie diet (approximately 500 kcal deficit daily) and encouraged 150 minutes of weekly physical activity [2]. Participants who adhered to these recommendations achieved better outcomes than those relying on medication alone.

Side Effects and Treatment Continuation

Gastrointestinal side effects—particularly nausea, diarrhoea, and constipation—represent the most common reason patients discontinue Mounjaro before achieving optimal results [1]. In clinical trials, approximately 4-7% of participants stopped treatment due to adverse events, most commonly during the dose escalation phase.

Your UK prescriber can adjust your escalation schedule if side effects become problematic, sometimes extending the time between dose increases to improve tolerance. Most gastrointestinal symptoms diminish significantly after 8-12 weeks as your body adapts to the medication [3]. Proper hydration, smaller meal portions, and avoiding high-fat foods help minimise these effects during the adjustment period.

Maintaining Mounjaro Results Long-Term

Weight maintenance after achieving your goal requires ongoing treatment in most cases. The SURMOUNT-4 trial examined what happens when patients discontinue tirzepatide after successful weight loss [5]. Participants who stopped treatment regained an average of 14% of their body weight over the following 52 weeks, whilst those continuing medication maintained their weight loss.

This pattern reflects the chronic nature of obesity as a medical condition rather than a medication failure. Tirzepatide works by modulating appetite hormones and metabolic signals that remain dysregulated in most people with obesity [5]. Discontinuing treatment allows these underlying mechanisms to reassert themselves, driving weight regain.

Long-term treatment plans typically involve continuing your effective maintenance dose indefinitely, similar to managing other chronic conditions like hypertension or high cholesterol. Your UK prescriber will conduct regular reviews to assess ongoing suitability, monitor for side effects, and adjust dosing as needed based on your individual response and health status.

Combining Medication with Lifestyle Changes

Sustainable results require integrating behavioural modifications alongside pharmacological treatment. Research shows patients who adopt structured eating patterns, regular physical activity, and stress management techniques achieve better long-term weight maintenance, even if they eventually reduce or discontinue medication [2].

At Cured Pharmacy, our UK clinical team can provide guidance on evidence-based lifestyle strategies that complement your Mounjaro treatment. This includes practical advice on portion control, nutrient-dense food choices, resistance training to preserve lean muscle mass during weight loss, and sleep hygiene—all factors that influence metabolic health and treatment outcomes.

Starting Mounjaro Treatment at Cured Pharmacy

Beginning your weight loss journey with Mounjaro requires a clinical assessment by a UK-registered prescriber to ensure the medication suits your individual health profile. At Cured Pharmacy, our free online consultation takes under 3 minutes and covers your medical history, current medications, weight loss goals, and any contraindications.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical services to ensure you receive genuine UK-licensed Mounjaro at competitive UK pricing. We provide transparent upfront costs—£135.00 for your prescribed dose—with no hidden fees or subscription traps. Your medication arrives in 100% discreet packaging via next-day delivery across the UK.

After starting treatment, you'll have access to ongoing support from our UK clinical team for questions about side effects, dose adjustments, or treatment progress. We recommend keeping a simple weight log and noting any side effects during your first 12 weeks, which helps your prescriber optimise your treatment plan during follow-up consultations.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–218. https://doi.org/10.1056/NEJMoa2206038
3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
5. Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W. Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., & Jastreboff, A. M. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.